Work

A phase 1 trial of D2C7-it in combination with an Fc-engineered anti-CD40 monoclonal antibody (2141-V11) administered intratumorally via convection-enhanced delivery for adult patients with recurrent malignant glioma (MG).

Year: 2022

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2022.40.16_suppl.e14015

Authors: Annick Desjardins, Vidyalakshmi Chandramohan, Daniel B Landi, Margaret O. Johnson, Mustafa Khasraw, Katherine B. Peters, Justin Low, James Emmett Herndon, Stevie Threatt, Chevelle A. Bullock, Eric S. Lipp, John H. Sampson, Allan H. Friedman, Henry S. Friedman, David M. Ashley, David Knorr, Darell D. Bigner

Institutions: Duke Medical Center, Duke University, Duke University Hospital, Duke Cancer Institute, Memorial Sloan Kettering Cancer Center

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

Funder: National Institutes of Health

OpenAlex ID: W4281772805

Cites:

Cited by: 11

Related to: 10